Related Experiment Video
Updated: May 21, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Problems and solutions for testing hemostasis assays while patients are on anticoagulants
1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Cà Granda Maggiore Hospital Foundation and Università degli Studi di Milano, Milano, Italy. armando.tripodi@unimi.it
Abstract:
Anticoagulant drugs affect directly or indirectly several coagulation parameters. This article is aimed at reviewing the problems encountered while testing patients on treatment and presents potential solutions. In general, it is recommended to postpone the performance of laboratory investigation upon discontinuation of the drug, preferably 2 days or more depending on the drug's half-life. If this strategy is unfeasible and patients remain on treatment, results of testing will likely be affected and result interpretation then requires great caution and knowledge of the peculiar and differential mechanism of action of the relevant anticoagulant drug being used.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

